US 11,813,270 B2
Nitric oxide-releasing antibacterial compounds, formulations, and methods pertaining thereto
Drew Folk, Durham, NC (US); Ryan Gerald Anderson, Morrisville, NC (US); John Kelly Simons, Cary, NC (US); Mona Jasmine Rosales Ahonen, Durham, NC (US); and Rebecca Anthouard McDonald, Chapel Hill, NC (US)
Assigned to KNOW BIO, LLC, Durham, NC (US)
Filed by KNOW BIO, LLC, Durham, NC (US)
Filed on Dec. 3, 2021, as Appl. No. 17/542,124.
Application 17/542,124 is a continuation of application No. 17/312,321, previously published as PCT/US2021/016854, filed on Feb. 5, 2021.
Claims priority of provisional application 62/971,624, filed on Feb. 7, 2020.
Prior Publication US 2022/0152063 A1, May 19, 2022
Int. Cl. A61K 31/655 (2006.01); A61P 31/00 (2006.01); A61K 33/24 (2019.01); A61K 39/42 (2006.01); A61K 45/06 (2006.01)
CPC A61K 31/655 (2013.01) [A61K 33/24 (2013.01); A61K 39/42 (2013.01); A61K 45/06 (2013.01); A61P 31/00 (2018.01)] 18 Claims
 
1. A method of treating a pulmonary bacterial infection caused by a bacteria, comprising administering an effective antibacterial amount of a compound having the following formula:

OG Complex Work Unit Chemistry
Formula I
wherein:
X is H or D,
and M+ is a pharmaceutically-acceptable cation selected from the group consisting of sodium, potassium, lithium, and quaternary ammonium salts,
to a patient in need of treatment thereof, wherein an effective antimicrobial amount of the compound is between 1 and 100 mg/kg, and
wherein the pulmonary bacterial infection is selected from the group consisting of Acetinobacter baumannii, Burkolderia cenocepacia, Escherichia coli, Haemophilus influenza, Mycobacterium abcessus, Pseudomonas aeruginosa, Staphylococcus aureus, and Streptococcus pyogenes.